Skip to Main Content

Author Details

Joel S Parker
Lineberger Cancer Center, University of North Carolina
2002
258
81
PMIDPaper TitleJournal TitlePublished Year
37944574Peripheral Blood IL5RA Gene Expression as a Diagnostic Biomarker for Eosinophilic Esophagitis.Clin Gastroenterol Hepatol2024
37944574Peripheral Blood IL5RA Gene Expression as a Diagnostic Biomarker for Eosinophilic Esophagitis.Clin Gastroenterol Hepatol2024
36222072Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis.Dis Esophagus2023
36222072Pre-treatment differential correlation of gene expression and response to topical steroids in eosinophilic esophagitis.Dis Esophagus2023
37672882Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.J Clin Oncol2023
37744358Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.Front Immunol2023
37923752Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.Nat Commun2023
37574209Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).Clin Cancer Res2023
36585450Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.Nat Cancer2023
36709390Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients.Pharmacogenomics J2023
37141389An integrated model for predicting KRAS dependency.PLoS Comput Biol2023
36576009HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.J Natl Cancer Inst2023
36798291Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.bioRxiv2023
36797360Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction.Commun Biol2023
36859416Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.Nat Commun2023
37103927Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.JAMA Oncol2023
37103916Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.JAMA Oncol2023
37744358Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.Front Immunol2023
37574209Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727).Clin Cancer Res2023
37923752Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.Nat Commun2023
37672882Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes.J Clin Oncol2023
37141389An integrated model for predicting KRAS dependency.PLoS Comput Biol2023
37103927Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.JAMA Oncol2023
37103916Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.JAMA Oncol2023
36859416Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.Nat Commun2023
36585450Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis.Nat Cancer2023
36576009HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.J Natl Cancer Inst2023
36709390Sequencing of genes of drug response in tumor DNA and implications for precision medicine in cancer patients.Pharmacogenomics J2023
36798291Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.bioRxiv2023
36797360Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction.Commun Biol2023
34843679Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas.J Invest Dermatol2022
36374768HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.EBioMedicine2022
35653148Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.Clin Cancer Res2022
35443752Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.Nat Commun2022
36216866Author Correction: Stretching muscle cells induces transcriptional and splicing transitions and changes in SR proteins.Commun Biol2022
35869079A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer.Nat Commun2022
35992833Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.Front Oncol2022
36123433Stretching muscle cells induces transcriptional and splicing transitions and changes in SR proteins.Commun Biol2022
35724320SET domain containing 2 (SETD2) influences metabolism and alternative splicing during myogenesis.FEBS J2022
34990895Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.EBioMedicine2022
34990404Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.J Clin Invest2022
35044810CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.J Clin Oncol2022
34965950Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.Clin Cancer Res2022
34843679Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas.J Invest Dermatol2022
35082143Alternative splicing regulation of membrane trafficking genes during myogenesis.RNA2022
35653148Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer.Clin Cancer Res2022
35443752Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.Nat Commun2022
35724320SET domain containing 2 (SETD2) influences metabolism and alternative splicing during myogenesis.FEBS J2022
35869079A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer.Nat Commun2022
35992833Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419.Front Oncol2022
  • 1 - 50 of 516

Recommended Authors

Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 1
Robert Lesurf
Ontario Institute for Cancer Research
Career Start Year 2008
Number of shared co-authors 11
David A Quigley
University of California-San Francisco
Career Start Year 2008
Number of shared co-authors 8
Qiyuan Li
National Institute of Data Science in Health and Medicine, Xiamen University
Career Start Year 2008
Number of shared co-authors 15
Ritu Roy
University of California San Francisco.
Career Start Year 2007
Number of shared co-authors 8
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 19
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 17
Joshy George
Peter MacCallum Cancer Centre
Career Start Year 2005
Number of shared co-authors 10
Gabriela Alexe
Dana-Farber Cancer Institute
Career Start Year 2004
Number of shared co-authors 17
Steffen Durinck
Genentech Inc.
Career Start Year 2004
Number of shared co-authors 11
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 5
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 31
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 37
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 42
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Howard H Yang
Center for Cancer Research, National Cancer Institute
Career Start Year 2002
Number of shared co-authors 6
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 10
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 25
Yan W Asmann
Mayo Clinic
Career Start Year 2000
Number of shared co-authors 20
Celine Lefebvre
The Scripps Research Institute
Career Start Year 1999
Number of shared co-authors 4
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 74
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 4
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 5
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 6
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 51
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 41
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 11
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 19
Jonathan R Pollack
Stanford University School of Medicine
Career Start Year 1987
Number of shared co-authors 19
Paul C Boutros
University of California los angeles
Career Start Year 1970
Number of shared co-authors 61

Collaborators

Charles M Perou
Co-authored papers 89
Lisa A Carey
Co-authored papers 30
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 29
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Co-authored papers 25
Cheng Fan
Co-authored papers 22
Lisle E Mose
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 16
Matthew J Ellis
Co-authored papers 16
Benjamin G Vincent
UNC School of Medicine, The University of North Carolina at Chapel Hill
Co-authored papers 15
Norman E Sharpless
National Cancer Institute
Co-authored papers 11
Elaine R Mardis
The Ohio State University
Co-authored papers 11
Carey K Anders
Co-authored papers 11
Matthew D Wilkerson
Uniformed Services University of the Health Sciences
Co-authored papers 11
Wendy Kimryn Rathmell
Co-authored papers 10
Jonathan S Serody
The University of North Carolina School of Medicine
Co-authored papers 10
Alan P Hoyle
Co-authored papers 10
Tomás Pascual
Co-authored papers 8
Matthew G Soloway
Co-authored papers 8
Sherri R Davies
Co-authored papers 7
Ian E Krop
Co-authored papers 7
James Todd Auman
Co-authored papers 7
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 7
Wendell G Yarbrough
University of North Carolina at Chapel Hill
Co-authored papers 6
Edward K Lobenhofer
Co-authored papers 6
Gary L Johnson
Co-authored papers 6
Stuart R Jefferys
Co-authored papers 6
Melissa A Troester
Co-authored papers 6
Gregory J Hannon
Co-authored papers 6
Christopher Ryan Miller
University of Illinois at Urbana-Champaign
Co-authored papers 6
Xiaobei Zhao
University of Tennessee Health Science Center
Co-authored papers 6
Samuel Leung
University of British Columbia
Co-authored papers 6
Release 1.2